KO-539 is expected to reduce the transcription of HOXA9 and MEIS1 promoters and lead to terminal differentiation of AML blasts following oral administration once daily in patients with MLL1-rearranged or NPM1-mutant AML cells. This evidence concerns the gene NPM1 and acute myeloid leukemia.